Colloral Type II collagen data

Investigators presented full data from the Lexington, Mass., company's Phase II study of Colloral, using three different measures of the drug's effect at doses of 20, 100, 500 and 2,500 µg/day and placebo.

Results were statistically significant based on the Paulus criteria, which showed the inverse dose response expected in a compound designed to induce oral tolerance. ...